Rifampin for a rare calcium disorder caused by CYP24A1
Treatments studied
Part of Genetic & congenital, Hormones & metabolism, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests rifampin to improve high blood and/or urine calcium that happens in people with CYP24A1 gene changes. It also checks safety by watching liver and kidney blood tests and pregnancy status.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 6 months and 65 years old
- You have at least one known CYP24A1 gene mutation
- Your blood and/or urine calcium is higher than normal for your age
- Your parathyroid hormone (PTH) blood test is below 20 pg/mL
- Your vitamin D level called 1,25-dihydroxy vitamin D3 is elevated or normal
- You are able and willing to follow study visits and procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called PTH-IA for people with a specific genetic mutation affecting the parathyroid hormone receptor. The study aims to see if the medication is safe and can help improve bone health in children and adults with this rare condition.
This study tests whether giving a personalized dose of rifampin (a key TB medicine) can improve treatment. It is for people with active TB that is sensitive to rifampin, and it involves frequent blood and urine tests to measure drug levels.
This study tests a vitamin D-like medicine for people with a specific genetic cause of low active vitamin D (CYP24A1 deficiency). If you have the right gene change, it may help your body use vitamin D more normally.
This trial tests a medicine called encaleret in children with a rare genetic condition that causes low calcium levels. The goal is to see if it safely helps control calcium and reduce symptoms.
This trial tests adding the antibiotic rifampin to standard treatment for staph infections on prosthetic heart valves. It aims to see if this combination improves outcomes.
This trial studies whether a rifapentine-based TB regimen can work just as well while shortening treatment time. It’s for people with rifampicin-sensitive, smear-positive lung tuberculosis.
Hear when a new Genetic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.